Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients
Phase 3
Completed
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2011-11-06
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 108
- Registration Number
- NCT01466192
- Locations
- 🇯🇵
Toranomon Hospital, Minato-ku, Tokyo, Japan
A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis
- First Posted Date
- 2011-08-30
- Last Posted Date
- 2015-12-14
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 490
- Registration Number
- NCT01425632
- Locations
- 🇯🇵
Reserch site, Kyusyu, Japan
Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: TA-7284 LowDrug: TA-7284 HighDrug: Placebo
- First Posted Date
- 2011-08-10
- Last Posted Date
- 2014-06-05
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 272
- Registration Number
- NCT01413204
- Locations
- 🇯🇵
Reserch site, Tohoku, Japan
Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: TA-7284-LowDrug: TA-7284-High
- First Posted Date
- 2011-07-06
- Last Posted Date
- 2014-06-06
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 1299
- Registration Number
- NCT01387737
- Locations
- 🇯🇵
Research site, Tohoku, Japan
Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 462
- Registration Number
- NCT01301833
Efficacy and Safety Study of MP-435 in Combination With Methotrexate (MTX) in Patients With Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2010-06-14
- Last Posted Date
- 2014-10-13
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 112
- Registration Number
- NCT01143337
- Locations
- 🇯🇵
Investigational site, Osaka, Japan
Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus
- First Posted Date
- 2010-02-22
- Last Posted Date
- 2013-04-09
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 99
- Registration Number
- NCT01072331
Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Placebo / Teneli (Teneligliptin) + pio (pioglitazone)Drug: Teneli / Teneli + pio
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2014-01-16
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 204
- Registration Number
- NCT01026194
An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: TA-7284-LowDrug: TA-7284-Low-middleDrug: TA-7284-High-middleDrug: TA-7284-HighDrug: Placebo
- First Posted Date
- 2009-12-01
- Last Posted Date
- 2014-06-05
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 383
- Registration Number
- NCT01022112
- Locations
- 🇯🇵
Research site, Tohoku, Japan
Monotherapy Study of MP-513 in Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-10-21
- Last Posted Date
- 2014-02-21
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 203
- Registration Number
- NCT00998881
© Copyright 2025. All Rights Reserved by MedPath